Cat. No.: DAB-0012773
| Product Information | |
|---|---|
| Clonality | Polyclonal |
| Host Species | Rabbit |
| Reactivity | Human, Mouse, Rat, Monkey |
| Applications | WB |
| Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to the sequence of human PTPA. Antibodies are purified by protein A and peptide affinity chromatography. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | PTPA |
| UniProt No. | Q15257 |
| Gene ID | 5524 |
| Gene Description | Protein phosphatase type 2A is an essential protein serine/threonine phosphatase that is conserved in all eukaryotes. PP2A is a key enzyme within various signal transduction pathways as it regulates fundamental cellular activities such as DNA replication, transcription, translation, metabolism, cell cycle progression, cell division, apoptosis and development. Active protein phosphatase 2A is composed of both structural and catalytic proteins, and its activity relies on interaction with regulatory subunits. An important PP2A regulatory subunit is PP2A phosphatase activator, also known as the PP2A activator regulatory subunit 4. This PTPA regulatory protein binds ATP and has isomerase activity, suggesting that PP2A regulation involves a change in phosphatase conformation. The addition of ATP results in a correlated increase in both PP2A activation and PTPA isomerase activity. While the exact mechanism is still under consideration, evidence suggests that binding of PTPA to the PP2A A-C dimer produces a conformational change in PP2A that shifts phosphatase substrate specificity from phosphoserine to phosphotyrosine substrates. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
